We are developing a first-in-class neuromodulator for ocular pain
Pioneering pharmacological blockade of PIEZO2 ion channels in ocular surface nerve endings
ABOUT
Innerva Pharmaceuticals is an innovative ophthalmic startup developing novel therapies for ocular pain
"Innerva Pharmaceuticals raises 2.3 million Euro in a round led by Inveready to develop a First in Class drug candidate for ocular surface pain"
MANAGEMENT TEAM
Prof. Carlos Belmonte
Co-founder & Advisor
Former Professor UMH, Founder and Director of the Institute of Neurosciences of Alicante; Past President of the International Brain Research Organization and the International Society for Ocular Research; Member of the Steering Committee of TFOS DEWS II; Royal Academy of Sciences; National Prize for Biomedical Research, co-founder Avizorex Pharma. Author of more than 150 scientific articles and 20 book chapters.
Patrick Tresserras
Co-founder & CEO
Former CEO Avizorex Pharma (acquired by Aerie Pharmaceuticals) developing AR-15512 (formerly AVX-012), currently in Phase 3 for Dry Eye Disease. Co-founder of Disrupt Therapeutics, a UPF Spin-off developing a novel drug candidate for Cognitive Impairment due to Medical Cannabis use in pain Management.
Ken Ford
Head of CMC
Pharmaceutical leader with over 25 years of professional experience in product development, scale-up, submissions and tech ops support.
Proven CMC team leader with multiple product approvals and launches including Xiidra®, Gardasil®, RotaTeq®, Invanz® and Juvisync®. Founder of CMC Tech, LLC.
Proven CMC team leader with multiple product approvals and launches including Xiidra®, Gardasil®, RotaTeq®, Invanz® and Juvisync®. Founder of CMC Tech, LLC.
Estefania Traver, PhD
Head of Preclinical Development and Regulatory
Professional with over 15 years of experience in the industry in mid pharma (SALVAT, Almirall), big pharma (Alexion, AstraZeneca) and biotech companies (Minoryx).
First, in drug discovery mainly in the ophthalmological space and, from 2015 on, in preclinical development and regulatory procedures with EMA and FDA.
First, in drug discovery mainly in the ophthalmological space and, from 2015 on, in preclinical development and regulatory procedures with EMA and FDA.
BOARD OF DIRECTORS
Patrick Tresserras
President
Carlos Belmonte
Board member
Diego Belmonte
Board member
María Poveda
Board member
INVESTORS
